Search

Search Constraints

You searched for: Author/Creator Maruzzo, Marco

Search Results

1. 265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort. (9th November 2020)

2. 265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort. (9th November 2020)

3. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. (February 2022)

6. Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study. (May 2022)

7. Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. Issue 2 (March 2021)

8. Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. Issue 1 (4th January 2023)

9. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). Issue 3 (June 2023)

10. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. Issue 2 (27th August 2020)